Zamudio-Coronado W, Gómez-Gutiérrez C, López-Ramírez Y, Juárez-Hernández E, Ramos-Ostos MH, Méndez-Sánchez N, Pérez-Jáuregui J, Uribe M, Chávez-Tapia N

Language: Spanish
References: 21
Page: 161-166
PDF size: 136.16 Kb.

ABSTRACT

Background. Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease. It has shown a relationship between elevated levels of uric acid and the presence of NAFLD. Some studies have shown an independent association between elevated levels of uric acid and development of NAFLD, and between hyperuricemia and degrees of severity of liver damage in patients with NAFLD. However, there’s insufficient evidence to link levels of uric acid with hepatic fibrosis in patients with NAFLD. Aim. To determine the association of high levels of uric acid and the presence of liver fibrosis in patients with NAFLD. Material and methods. A case study nested in a randomized clinical trial (NCT01874249) study was conducted. The sample included 386 patients attending the Integral Diagnostic and Treatment Center (CIDyT) of the Medica Sur & Clinic Foundation in the period of January 2012 to March 2013, patients were diagnosed by ultrasound. Control patients where those NAFLD without hyperuricemia, and cases those with hyperuricemia patients and NAFLD. Noninvasive methods for diagnosing liver fibrosis were used by NAFDL score in the total population and 144 patients with transient elastography. Results. The comparative analysis of the two groups showed that the main risk factors associated with hyperuricemia in patients with NAFLD are the high body mass index (BMI) (30.92 ± 2.78 kg/m² vs. 29.36 ± 2.46 kg/m², p = 0.0001) and metabolic syndrome (62.7 vs. 43.3%, p = 0.0006). No significant associations between the presence of hyperuricemia and hepatic fibrosis were found. Conclusion. In this case-control study, no association between hyperuricemia and hepatic fibrosis was found in patients with NAFLD.

REFERENCES

1. Chon CW, Kim BS, Cho YK, Sung KC, Bae JC, Kim TW, Won HS, et al. Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men. Gut Liver 2012; 6: 368-73.

2. Medina-Santillan R, Lopez-Velazquez JA, Chavez-Tapia N, Torres-Villalobos G, Uribe M, Mendez-Sanchez N. Hepatic manifestations of metabolic syndrome. Diabetes Metab Res Rev 2013.

3. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of nonalcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002; 34: 204-11.

4. Lopez-Velazquez JA, Silva-Vidal KV, Ponciano-Rodriguez G, Chavez-Tapia NC, Arrese M, Uribe M, Mendez-Sanchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol 2014; 13: 166-78.

5. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009; 50: 1029-34.

6. Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J Korean Med Sci 2011; 26: 386-91.

7. Chavez-Tapia NC, Rosso N, Uribe M, Bojalil R, Tiribelli C. Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Ann Hepatol 2013; 13: 113-20.

8. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-21.

9. Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010; 52: 578-89.

10. Cai W, Wu X, Zhang B, Miao L, Sun YP, Zou Y, Yao H. Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China. Arq Bras Endocrinol Metabol 2013; 57: 617-22.

11. Petta S, Camma C, Cabibi D, Di Marco V, Craxi A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34: 757-66.

12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

13. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.

14. Salas-Salvado J, Rubio MA, Barbany M, Moreno B. [SEEDO 2007 Consensus for the evaluation of overweight and obesity and the establishment of therapeutic intervention criteria]. Med Clin (Barc) 2007; 128: 184-96; quiz 181 p following 200.

15. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.

16. de Ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol 2008; 32: 58-67.

17. Standards of medical care in diabetes–2014. Diabetes Care 2014; 37(Suppl. 1): S14-S80.

18. Cai W, Song JM, Zhang B, Sun YP, Yao H, Zhang YX. The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. Scientific World Journal 2014; 2014: 393628.

19. Yamada T, Suzuki S, Fukatsu M, Wada T, Yoshida T, Joh T. Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup. Acta Gastroenterol Belg 2010; 73: 12-7.

20. Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, Kara M, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem 2014; 47: 383-8.

21. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011; 13: 160-6.